Stay updated with breaking news from Eric Endicott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer's disease DUBLIN, Ireland, April 26, 2022 (GLOBE
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease ... | March 28, 2022
Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer's disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA)